COLL - COLLEGIUM PHARMACEUTICAL, INC
IEX Last Trade
28.96
-0.030 -0.104%
Share volume: 3,031
Last Updated: Fri 27 Dec 2024 05:29:51 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.45%
PREVIOUS CLOSE
CHG
CHG%
$28.99
-0.03
-0.10%
Fundamental analysis
74%
Profitability
76%
Dept financing
48%
Liquidity
74%
Performance
77%
Performance
5 Days
-0.31%
1 Month
-6.83%
3 Months
-24.46%
6 Months
-8.70%
1 Year
-3.81%
2 Year
26.57%
Key data
Stock price
$28.96
DAY RANGE
$28.94 - $29.50
52 WEEK RANGE
$29.26 - $42.29
52 WEEK CHANGE
-$5.65
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Joseph J. Ciaffoni
Region: US
Website: collegiumpharma.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: collegiumpharma.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Collegium Pharmaceutical, Inc. develops and commercializes medicines for pain management. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone.
Recent news